Author + information
- Received February 21, 2006
- Accepted February 21, 2006
- Published online July 4, 2006.
- Susanne B. Haga, PhD⁎ ( and )
- Geoffrey S. Ginsburg, MD, PhD
- ↵⁎Reprint requests and correspondence:
Dr. Susanne B. Haga, Senior Policy Scientist, Institute for Genome Sciences & Policy, Duke University, 101 Science Drive, Box 3382, Durham, North Carolina 27708.
The approval of BiDil as an adjunct treatment in self-identified blacks with heart failure raises questions regarding the underlying etiology of drug response in this target population and the ability to accurately identify patients who are most likely to benefit. Preliminary data have indicated that differences in nitric oxide synthesis between groups may account for differences in response to BiDil and genetic studies have begun to elucidate the mechanism of these differences. Until more accurate selection criteria are developed to identify patients who are most likely to benefit, both clinicians and the general public will need to consider the unique issues raised by BiDil.
Supported by the Duke Institute for Genome Sciences & Policy. Richard L. Popp, MD, MACC, served as Guest Editor for this paper.
- Received February 21, 2006.
- Accepted February 21, 2006.
- American College of Cardiology Foundation